Raymond James analyst Jason Bednar maintains Intuitive Surgical (NASDAQ:ISRG) with a Outperform and raises the price target from $310 to $372.
Raymond James raises Intuitive Surgical (NASDAQ:ISRG) price target from $310 to $372 Read Post »
Intuitive Surgical (NASDAQ:ISRG) stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/22/2023 16.71% Truist Securities $375 → $390 Maintains Buy 12/12/2023 12.23% Truist Securities $320 → $375 Maintains Buy 12/04/2023 -1.24% Morgan Stanley $300 → $330 Maintains Equal-Weight 11/17/2023 4.74% Stifel $315 → $350 Maintains Buy 11/17/2023 -4.83% HSBC → $318 Initiates Coverage On → Buy 10/23/2023 -10.22% Morgan Stanley $330 → $300 Maintains Equal-Weight 10/20/2023 -2.74% Piper Sandler $385 → $325 Maintains Overweight 10/20/2023 6.24% RBC Capital → $355 Reiterates Outperform → Outperform 10/20/2023 16.71% Citigroup $400 → $390 Maintains Buy 10/20/2023 8.63% Wells Fargo $386 → $363 Maintains Overweight 10/20/2023 -7.23% Raymond James $368 → $310 Maintains Outperform 10/16/2023 2.35% Leerink Partners → $342 Initiates Coverage On → Outperform 08/17/2023 7.74% RBC Capital → $360 Reiterates Outperform → Outperform 07/24/2023 -1.24% Morgan Stanley $310 → $330 Maintains Equal-Weight 07/24/2023 15.22%
Intuitive Surgical (NASDAQ:ISRG) stock Analyst Ratings Read Post »
Eli Lilly Company (NYSE: LLY) Stock Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/21/2023 6.79% Daiwa Capital → $610 Downgrades Buy → Outperform 11/29/2023 13.79% Truist Securities → $650 Reiterates Buy → Buy 11/20/2023 10.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/17/2023 10.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/15/2023 10.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 11/09/2023 -6.34% Deutsche Bank → $535 Initiates Coverage On → Hold 11/08/2023 — JP Morgan Reiterates → Overweight 11/03/2023 26.39% Morgan Stanley $673 → $722 Maintains Overweight 10/23/2023 18.16% Citigroup $525 → $675 Maintains Buy 10/23/2023 10.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 10/20/2023 24.29% UBS $612 → $710 Assumes Buy → Buy 10/11/2023 17.81% Morgan Stanley $640 → $673 Maintains Overweight 10/09/2023 10.29% Cantor Fitzgerald → $630 Reiterates Overweight → Overweight 10/09/2023 13.79% Wells Fargo $615
Eli Lilly Company (NYSE: LLY) Stock Analyst Ratings Read Post »
UnitedHealth Group (NYSE:UNH) Analyst Ratings Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/18/2023 -8.92% HSBC $550 → $480 Downgrades Hold → Reduce 12/13/2023 11% Stephens & Co. → $585 Reiterates Overweight → Overweight 11/30/2023 15.75% Truist Securities → $610 Reiterates Buy → Buy 11/30/2023 13.09% RBC Capital → $596 Reiterates Outperform → Outperform 11/30/2023 11% Stephens & Co. → $585 Reiterates Overweight → Overweight 11/21/2023 12.14% Cantor Fitzgerald → $591 Reiterates Overweight → Overweight 11/20/2023 -4.56% Jefferies $565 → $503 Maintains Hold 10/23/2023 9.87% Morgan Stanley $587 → $579 Maintains Overweight 10/16/2023 13.09% RBC Capital $572 → $596 Maintains Outperform 10/16/2023 10.81% Piper Sandler $580 → $584 Maintains Overweight 10/16/2023 21.44% UBS → $640 Upgrades Neutral → Buy 10/09/2023 0.76% Jefferies $529 → $531 Maintains Hold 09/14/2023 12.14% Cantor Fitzgerald → $591 Reiterates Overweight → Overweight 09/06/2023 2.46% HSBC → $540 Initiates Coverage On
UnitedHealth Group (NYSE:UNH) Analyst Ratings Read Post »
HSBC analyst Rajesh Kumar downgrades UnitedHealth Group (NYSE:UNH) from Hold to Reduce and lowers the price target from $550 to $480.
HSBC lowers UnitedHealth Group (NYSE:UNH) price target from $550 to $480 Read Post »
Pfizer (PFE) said Tuesday it expects to close its planned acquisition of Seagen (SGEN) on Thursday as it has received all required regulatory approvals. The company said it plans to donate the royalty rights from US sales of Bavencio to the American Association for Cancer Research in a bid to address antitrust concerns raised by the US Federal Trade Commission. The pharmaceutical company said it will adapt its commercial organization to integrate Seagen, effective Jan. 1. This involves forming the Pfizer Oncology Division, which will integrate certain oncology commercial and R&D functions from both companies and be led by Chris Boshoff as chief oncology officer. Pfizer said it will split its non-oncology commercial operations into two divisions: Pfizer US Commercial, led by Aamir Malik as chief US commercial officer, and Pfizer International Commercial, headed by Alexandre de Germay as chief international commercial officer. Germay most recently served as CEO of
Pfizer Says Seagen Deal to Close Thursday; Commercial Operations to Be Restructured Read Post »
Pfizer CFO Says Share Repurchases Are The Lowest Priority At This Time.
Pfizer CFO Says Share Repurchases Are The Lowest Priority At This Time Read Post »
Pfizer CFO Says Co Is Close To Presenting Data On Its Oral Weight Loss Drug As Previously Expected, Likely By The End Of The Year.
Pfizer Inc. (NYSE:PFE) Truist Securities BioPharma Symposium November 9, 2023 12:35 PM ET Company Participants Aamir Malik – Executive Vice President and Chief Business Innovation Officer Conference Call Participants Robyn Karnauskas – Truist Securities Robyn Karnauskas Good afternoon. Thanks so much for joining us. I’m Robyn Karnauskas, one of the biotech analysts at Truist. I’m so excited to have for a keynote this afternoon from Pfizer, Aamir Malik, the Chief Business Innovation Officer and Executive Vice President. So thank you very much for taking the time and doing this talk instead of doing more important things. I really appreciate it. Aamir Malik It’s nice to be with you. Thanks for having me. Question-and-Answer Session Q – Robyn Karnauskas So I guess the first question is, given your role as the Chief Business Innovation Officer, how do you see Pfizer’s approach to innovation compared to other pharma companies? And how does
Pfizer Inc. (PFE) Presents at Truist Securities BioPharma Symposium (Transcript) Read Post »
Morgan Stanley analyst David Phung maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $673 to $722.
Morgan Stanley raises Eli Lilly (NYSE:LLY) price target from $673 to $722 Read Post »
Company Management Anat Ashkenazi – EVP & CFO Anne White – EVP & President, Lilly Neuroscience Lilly Research Laboratories Daniel Skovronsky – EVP, Chief Scientific & Medical Officer and President David Ricks – Chairman, CEO & President Ilya Yuffa – EVP of Eli Lilly and Company and President of Lilly International Joe Fletcher – SVP, IR Michael Mason – EVP & President of Lilly Diabetes Analysts Carter Gould – Barclays Bank Chris Shibutani – Goldman Sachs Group Christopher Schott – JPMorgan Chase & Co. David Risinger – Leerink Partners Evan Seigerman – BMO Capital Markets Geoff Meacham – Bank of America Merrill Lynch Laura Hindley – Berenberg Louise Chen – Cantor Fitzgerald & Co. Mohit Bansal – Wells Fargo Securities Seamus Fernandez – Guggenheim Stephen Scala – TD Cowen Terence Flynn – Morgan Stanley Timothy Anderson – Wolfe Research Trung Huynh – UBS Umer Raffat – Evercore ISI Timothy Anderson
Eli Lilly and Co Q3 2023 Earnings Conference Call Transcript Read Post »
Eli Lilly Q3 Adj. EPS 10 Cents Vs. $1.98 a Year Ago, Beats FactSet Consensus for Per-share Loss 18 Cents.